Dosage guide · 10 mg vial

TB-500 Dosage Protocol

Thymosin beta-4 17–23 fragment · Ac-LKKTETQ research peptide

The reference protocol shows 500 mcg once daily for weeks 1–2, then 600 mcg, 750 mcg and 1,000 mcg in later steps. With 3 mL of bacteriostatic water, a 10 mg vial is 3.33 mg/mL, so the 500 mcg starting amount is 15 units (0.15 mL) on a U-100 syringe. These are community-reported amounts, not a clinically established human dose.

How oftenOnce daily

Starting dose500 mcg

Start = units15 units

Mix3 mL BAC water

Reviewed 25 Oct 2026 · Education only, not medical advice

TB-500 10 mg vial

View on Peak Peptides

Exact Peak Peptides Australia product photo

Dosage chart How to mix Supplies Calculator About TB-500 References

01 · DOSAGE CHART

TB-500 dosage chart

Gradual daily approach · 10 mg vial + 3 mL BAC water

BAC water added

Concentration3.33 mg/mL

1 unit (U-100)33.3 mcg= 0.01 mL

How oftenOnce dailySubcutaneous injection

3 mL is shown on Peak's page and in the matching 10 mg reference protocol, making 1 mg 30 units.

TB-500 dosage chart for a 10 mg vial mixed with 3 mL of bacteriostatic water
Week	Daily dose	Syringe units
Weeks 1–2Start	500 mcg	15 units0.15 mL
Weeks 3–4	600 mcg	18 units0.18 mL
Weeks 5–8	750 mcg	22.5 units0.225 mL
Weeks 9–12Max	1 mg	30 units0.3 mL

Once daily · subcutaneous injection

The reference protocol steps up every 2 to 4 weeks and shows one administration each day.

Its chart runs through week 12; do not assume a longer course is established by human research.

Community-reported amounts — TB-500 has no clinically established human dose. Education only, not medical advice. Dose amounts adapted from TB-500 10 mg vial dosage protocol (PeptideDosages.com); units are recalculated for the vial and mix selected above.

02 · HOW TO MIX

Mixing a 10 mg vial with 3 mL of BAC water

Using a 1 mL (100-unit) insulin syringe, 3 full draws of bacteriostatic water gives 3.33 mg/mL.

1
Add the water slowly
Wipe both rubber stoppers with an alcohol swab and let them dry. Draw 3 mL of bacteriostatic water and let it run slowly down the inside of the vial wall — not straight onto the powder.
2
Swirl gently
Swirl or roll the vial gently until the powder has dissolved. Give it a few minutes to settle if needed.
3
Don't shake it
Shaking can damage the peptide and cause foaming. Gentle swirling only.
4
Check it's fully clear
Only use it once it is fully clear with no particles. Label the vial with the date and 3.33 mg/mL, then store it in the fridge at 2–8 °C.

Full illustrated reconstitution guide

03 · SUPPLIES NEEDED

What you'll need

Counts follow the dosage chart above at the highest amount in each step, using a 10 mg vial mixed with 3 mL.

Length of protocol

4TB-500 10 mg vials36.4 mg needed in total

601 mL insulin syringesU-100, 27–31G · one per draw + one per vial mixed

2BAC water 10 mL bottles12 mL used for mixing

120Alcohol swabsSkin + stopper, every time

Plus an approved sharps container. Syringes and swabs are sold by Australian pharmacies — Peak Peptides and Pure Performance supply the bacteriostatic water.

TB-500 10 mg vialPeak Peptides Australia

Peak Peptides Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPeak Peptides Australia

Pure Performance Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPure Performance Australia

04 · CALCULATOR

Check a different amount

Enter your vial, water and dose to see the matching syringe units.

Concentration Calculator

Labelled Vial Amount (mg)

Verified Final Liquid Volume3 mL

Amount to Evaluate (not a recommendation)

mcg

Concentration

3.33 mg/mL

(3333 mcg/mL)

Calculated Liquid Volume

0.150 mL

Equivalent U-100 volume scale position

15markings (not biological IU)

Illustration of a U-100 volume scale, not preparation or injection guidance

05 · PROTOCOL DETAILS

About TB-500

Protocol overview

Starting amount: 500 mcg once daily for weeks 1–2
How it increases: 600 mcg in weeks 3–4, 750 mcg in weeks 5–8, then 1,000 mcg in weeks 9–12
Frequency: Once daily
Timing: The reference protocol does not specify a time of day
Chart length: 12 weeks shown; supplies can be estimated for 8, 12 or 16 weeks
Common mix: 3 mL bacteriostatic water → 3.33 mg/mL

Storage

Before mixing: Peak advises storing unopened lyophilised powder in the fridge at 2–8 °C in the dark; it describes −20 °C as a long-term option.
After mixing: Peak advises keeping the mixed vial upright in the fridge at 2–8 °C, away from light, and using it within about 4 weeks (28 days).
Never: Do not freeze the mixed vial or use it if it has unexpected cloudiness, particles, discoloration, leakage or container damage.

How it works

TB-500 is the common name for an N-terminally acetylated, seven-amino-acid fragment of full-length thymosin beta-4, Ac-LKKTETQ. It is not the same molecule as the 43-amino-acid thymosin beta-4 protein.

The fragment contains sequence associated with an actin-binding region of full-length thymosin beta-4. FDA notes that acetylation can change a peptide's properties, so findings for non-acetylated LKKTETQ or full-length thymosin beta-4 cannot be directly applied to TB-500.

In a rat wound model, full-length thymosin beta-4 increased re-epithelialisation and angiogenesis. That animal finding does not establish that TB-500 repairs human tissue.

Illustrated mechanism explainer

What the research shows

FDA's 2026 TB-500 evaluation identifies it as the N-acetylated 17–23 fragment of thymosin beta-4 and found no human clinical studies or human exposure data for TB-500 by any route.
FDA reports that neither TB-500 free base nor TB-500 acetate is a component of an FDA-approved drug, and that no approved products containing TB-500 were identified in Australia.
A human trial of a different material, recombinant full-length thymosin beta-4, gave 54 healthy adults single intravenous doses of 0.05–25 micrograms/kg and 30 adults daily intravenous doses of 0.5–5 micrograms/kg for 10 days. It does not establish safety, route or dose for TB-500.
In a rat full-thickness wound model using full-length thymosin beta-4 rather than TB-500, re-epithelialisation was 42% higher than saline at day 4 and up to 61% higher at day 7. This is animal evidence, not evidence of a human TB-500 effect.
The Australian Poisons Standard lists TB-500 and thymosin beta-4 in Schedule 4 and Appendix D clause 5. WADA lists thymosin-beta4 and its derivatives, including TB-500, under S2.3 as prohibited at all times.

Reported side effects

There are no identified human clinical studies or human exposure data for TB-500, so its adverse-effect profile in people is unknown.
FDA identifies a potential risk of immune reactions with injectable TB-500 because peptides can aggregate and contain peptide-related impurities.
FDA found no acute- or repeat-dose toxicity studies for TB-500 free base or acetate in its evaluation, so an absence of reports is not evidence that it is harmless.
Mild-to-moderate adverse events reported in the full-length thymosin beta-4 intravenous trial cannot be used to predict TB-500 effects because the material and route differ.

Important notes

Not an approved medicine: FDA's 2026 review found TB-500 is not part of an FDA-approved drug and identified no approved TB-500 products in Australia.
Australian legal status matters: the current Poisons Standard lists TB-500 in Schedule 4 and Appendix D clause 5; Appendix D says possession without authority is illegal, with state and territory laws also applying.
Prohibited in sport at all times: WADA includes thymosin-beta4 and its derivatives, including TB-500, in S2.3.
The chart is copied from a community-reported reference protocol, not from a human dose-finding programme. Full-length thymosin beta-4 research does not validate this fragment's dose, route or duration.
Never use a mixed vial that is cloudy or has particles in it.

Injection basics

Use a new sterile 1 mL (100-unit) U-100 insulin syringe, 27–31G, every time — never reuse or share.
Wipe the vial stopper and the skin with an alcohol swab and let both dry first.
Inject under the skin (subcutaneously) of the abdomen, thigh or upper arm, and rotate sites.
Put used syringes straight into an approved sharps container — the NDSS lists Australian disposal options.

Guidance: World Health Organization · National Diabetes Services Scheme (NDSS)

06 · QUICK ANSWERS

TB-500 questions

How many units is 500 mcg of TB-500?

With 3 mL in a 10 mg vial, the concentration is 3.33 mg/mL. A 500 mcg amount is 15 units, or 0.15 mL, on a U-100 syringe. This is a volume conversion only.

How much bacteriostatic water for a 10 mg TB-500 vial?

The matching 10 mg reference protocol and Peak's calculation example use 3 mL. That gives 3.33 mg/mL; 30 units is 0.30 mL and contains 1 mg.

How many units are the later TB-500 chart amounts?

At the default 10 mg plus 3 mL mix, 600 mcg is 18 units (0.18 mL), 750 mcg is 22.5 units (0.225 mL), and 1,000 mcg is 30 units (0.30 mL).

How long does a 10 mg TB-500 vial last?

At a fixed daily amount, a 10 mg vial contains 20 amounts of 500 mcg, about 16.7 amounts of 600 mcg, about 13.3 amounts of 750 mcg, or 10 amounts of 1,000 mcg. The staged chart uses more than one amount, so actual use varies.

07 · SOURCES